Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$2.83M-$2.83MN/M vs Q1 2024 EPS Diluted-$7.58-$7.58N/M vs Q1 2024 Operating Income-$2,846,990N/M Operating Cash Flow-$2,729,848N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end